The Patent Trial and Appeal Board (PTAB) has initiated a review of a patent related to a blood medication owned by Alexion. The decision comes after PTAB found that the company had presented “incomplete and inaccurate” information to an examiner at the U.S. Patent and Trademark Office (USPTO). The alleged ‘misleading’ provided by Alexion has brought the validity of the patent into question.
Details concerning the nature of the misleading information or the specific blood drug patent under scrutiny are currently under investigation and limited. However, what is apparent is that PTAB’s decision marks a significant moment in the continuing discourse about patent transparency and ethical practices in the biopharmaceutical industry. Such reviews are pivotal to ensuring that the patent registration process is upheld to the highest standards and that the information provided during the process is both accurate and complete.
Alexion, a global biopharmaceutical company, is well-known for its research and development efforts in rare diseases, particularly in the field of Hematology. Its experience and contributions to the field make the current PTAB review of its patent quite noteworthy.
Additional specifics on the proceedings and next steps in PTAB’s review can be found in the full report at Law360.